Skip to main content
. 2017 Jul-Sep;33(3):317–323. doi: 10.4103/joacp.JOACP_299_16

Figure 1.

Figure 1

Kaplan–Meyer curves for recurrence-free survival (top) and overall survival (bottom). The figure depicts the Kaplan–Meier curves for recurrence-free survival (top) and overall survival (bottom) of the matched population of patients. As it can be appreciated patients who received dexmedetomidine had shorter overall survival than those who did not received the drug. Recurrence-free survival was similar in both groups of patients